Crispr Therapeutics AG's total assets for Q1 2025 were $2.17B, a decrease of -3.39% from the previous quarter. CRSP total liabilities were $336.94M for the fiscal quarter, a 8.71% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.